Wolverine Trading’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-17,000
Closed -$105K 7387
2021
Q3
$105K Buy
+17,000
New +$106K ﹤0.01% 5749
2021
Q2
Sell
-11,100
Closed -$96K 7081
2021
Q1
$96K Buy
+11,100
New +$127K ﹤0.01% 5452
2020
Q3
Sell
-14,400
Closed -$183K 5427
2020
Q2
$183K Sell
14,400
-12,000
-45% -$124K ﹤0.01% 3882
2020
Q1
$217K Sell
26,400
-33,600
-56% -$506K ﹤0.01% 3602
2019
Q4
$1.23M Buy
60,000
+35,000
+140% +$590K ﹤0.01% 2219
2019
Q3
$348K Buy
25,000
+11,700
+88% +$139K ﹤0.01% 3010
2019
Q2
$164K Sell
13,300
-1,200
-8% -$13.8K ﹤0.01% 3821
2019
Q1
$181K Sell
14,500
-6,700
-32% -$89.5K ﹤0.01% 3899
2018
Q4
$252K Buy
21,200
+6,800
+47% +$107K ﹤0.01% 3417
2018
Q3
$269K Buy
+14,400
New +$331K ﹤0.01% 3878
2018
Q1
Sell
-10,800
Closed -$270K 6113
2017
Q4
$270K Sell
10,800
-6,500
-38% -$159K ﹤0.01% 3774
2017
Q3
$418K Sell
17,300
-4,000
-19% -$94K ﹤0.01% 2824
2017
Q2
$438K Buy
21,300
+9,400
+79% +$196K ﹤0.01% 2577
2017
Q1
$322K Sell
11,900
-1,500
-11% -$30.6K ﹤0.01% 2938
2016
Q4
$255K Buy
+13,400
New +$256K ﹤0.01% 3447

Wolverine Trading's FLXN Position: Q4 2019 in Review

Wolverine Trading sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2019, closing a stake of 18,460 shares — an estimated $311K sold.

Wolverine Trading first reported a position in FLXN in Q1 2017 and held it in 8 quarters. The position peaked at $422K in Q4 2018. 133 funds tracked by Wall St. Rank hold FLXN as of Q4 2019.

  • Wolverine Trading reported no remaining Flexion Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Wolverine Trading sold 18,460 Flexion Therapeutics, Inc. shares in Q4 2019, an estimated $311K.
  • Wolverine Trading first reported a position in Flexion Therapeutics, Inc. in Q1 2017 and held it in 8 quarters.
  • Wolverine Trading's Flexion Therapeutics, Inc. position peaked at $422K in Q4 2018.
  • 133 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2019.

Based on Wolverine Trading's 13F filing for Q4 2019, filed 12 Feb 2020.